Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation

Clinical Transplantation

Volumn 18, Issue 5, 2004, Pages 493-496

  Joyal, Dominique ^a   Cantarovich, Marcelo ^a   Cecere, Renzo ^a   Giannetti, Nadia ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Daclizumab; Transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; HUMAN MONOCLONAL ANTIBODY; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMODYNAMICS; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; OUTPATIENT CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DRUG COSTS; FOLLOW-UP STUDIES; GRAFT REJECTION; HALF-LIFE; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; PRODRUGS; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 4644232019     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00189.x     Document Type: Article

References (15)

1. Kobashigawa J, Miller L, Renlund D et al. A randomised active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998: 68: 708-9.
2. Berard JL, Velez RL, Freeman RB, Tsunoda SM. A review of Interleukin-2 Receptor Antagonists in Solid Organ Transplantation. Pharmacotherapy 1999: 19: 1127-1137.
3. Vincenti F, Kirkman R, Light S et al. Interleukin-2 receptor blockage with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161.
4. Beniaminovitz A, Itescu S, Lietz K et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000: 342: 613-9.
5. Vincenti F, Lantz M, Birnbaum J et al. A phase-1 trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997: 63: 33-38.
6. Ter Meulen CG, Baan CC, Hené RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged interleukin-2Rα chain blockade. Transplantation 2001: 72: 1709-1710.
7. Eckhoff DE, McGuire B, Sellers M et al. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 2000: 69: 1867-1872.
8. Niemeyer G, Koch M, Light S, Kuse ER, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transpl 2002: 2: 454-460.
9. Amlot PL, Rawlings E, Fernando ON et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995: 60: 748-56.
10. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002: 73: 1640-1646.
11. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation 1999: 67: 276.
12. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou J-P. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997: 350: 1193.
13. Kovarik JM, Pescovitz MD, Sollinger HW et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplantation 2001: 15: 123-130.
14. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplantation 2003: 17: 144-150.
15. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. N Engl J Med 2003: 349: 847-58.